AEZS-108: Additional Phase II data

Data from an undisclosed number of evaluable LHRH-positive endometrial cancer patients in the second stage of the open-label, European Phase II AGO-GYN-5 trial showed that AEZS-108 met the primary endpoint of >=5 patients with partial or complete response as determined by RECIST criteria. Patients received six 3-week cycles of 267 mg/m 2 IV AEZS-108. The company plans to enroll a total of 41 endometrial cancer patients in the study. The company previously reported that AEZS-108 produced 1 complete response and 2 partial responses in 14 endometrial cancer patients in the first stage of the trial (see BioCentury, Nov. 10, 2008). ...